Navigation Links
Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
Date:11/5/2010

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced a free Sermo Report titled, "Treatment Options for Gout". The report gathered feedback from physicians to better understand how they currently treat gout and if they would consider using new treatments.  

While many physicians who participated felt that current gout treatments effectively manage acute and suppressed gout flares, 63% confirmed they would utilize new gout medications as they become available. Physicians also listed many different patient types that would benefit from new gout treatments, including recurrent gouty arthritis, tophaceous gout and those resistant to current treatments.

This free Sermo Report polled 114 physicians across multiple specialties, of which 89% see an average of 19 gout patients per month. Many of the respondents also participated in an online discussion regarding various treatment strategies and how they plan to use newly available therapies.

The full reports includes:

  • Key Findings
  • Physician Demographics
  • Discussion Highlights
  • Quantitative and Qualitative Post Analysis

Companies that are in the process of developing or have approved gout treatments include Takeda Pharmaceuticals, Savient Pharmaceuticals, Cardiome Pharma Corp., Regeneron Pharmaceuticals, Ardea Biosciences and Novartis.

To download full results of this free report, visit sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, trends, and other topics of interest. Data for Sermo Reports is
gathered through Sermo Posts, which allow physicians to participate in a poll and comment on the topic.  All physicians on Sermo are verified and credentialed.

About Sermo

Sermo is the largest online physician community, where over 117,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into unsolicited, peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit www.sermo.com/client.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
8. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
9. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
Breaking Medicine News(10 mins):